Kiora Pharmaceuticals (NASDAQ:KPRX) Posts Earnings Results, Beats Expectations By $0.13 EPS

Kiora Pharmaceuticals (NASDAQ:KPRX) announced its earnings results on Friday. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.13, FiscalAI reports.

Kiora Pharmaceuticals Price Performance

NASDAQ KPRX traded up $0.08 during mid-day trading on Friday, hitting $2.64. The stock had a trading volume of 23,543 shares, compared to its average volume of 22,446. The firm’s 50 day moving average is $2.57 and its 200 day moving average is $2.37. Kiora Pharmaceuticals has a twelve month low of $1.76 and a twelve month high of $3.01. The stock has a market capitalization of $11.70 million, a price-to-earnings ratio of -0.97 and a beta of -0.38.

Institutional Investors Weigh In On Kiora Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in KPRX. Two Sigma Investments LP acquired a new stake in shares of Kiora Pharmaceuticals in the third quarter valued at about $33,000. Renaissance Technologies LLC lifted its stake in shares of Kiora Pharmaceuticals by 71.0% in the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after buying an additional 8,800 shares in the last quarter. Citadel Advisors LLC acquired a new position in Kiora Pharmaceuticals during the third quarter worth about $125,000. Alyeska Investment Group L.P. acquired a new position in Kiora Pharmaceuticals during the fourth quarter worth about $152,000. Finally, DRW Securities LLC grew its stake in Kiora Pharmaceuticals by 199.2% during the 4th quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after acquiring an additional 73,417 shares in the last quarter. Institutional investors and hedge funds own 76.97% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $10.00.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.